Biocept Akcija

Biocept Goodwill

Delisted

Iegūtā prēmija no Biocept (BIOC) uz 2026. g. 22. aug..

Goodwill

0,00USD

Pēdējoreiz atjaunināts:

Iegūtā prēmija no Biocept ir 2026 0,00 USD. Iegūtā prēmija no Biocept bija 2025 0,00 USD. Tas samazinās par % zemāks salīdzinājumā ar iepriekšējo gadu.

Biocept Goodwill vēsture

  • 3 gadi

  • 10 gadi

  • 25 gadi

  • Max

Goodwill
Date
Goodwill
2014. g. 1. janv.
0,00 USD
2015. g. 1. janv.
0,00 USD
2016. g. 1. janv.
0,00 USD
2017. g. 1. janv.
0,00 USD
Biocept Goodwill vēsture
GADSGoodwillYoY
0,00USD
0,00USD
0,00USD
0,00USD
Access this data via the Eulerpool API

Biocept Akciju analīze

Ko dara Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept ir viens no populārākajiem uzņēmumiem Eulerpool.

Bieži uzdotie jautājumi par Biocept akciju

Vietnē Eulerpool varat atrast pilnīgu Iegūtā prēmija Biocept vēsturisko attīstību kopš 2006. gada — ar gada vērtībām, grafikiem un detalizētu analīzi.

Nemateriālā vērtība rodas iegādes darījumos, kad samaksātā cena pārsniedz iegūto neto aktīvu patieso vērtību.

Rādītāji ietekmē akciju vērtējumu, signalizējot par peļņas kvalitāti, finansiālo veselību un izaugsmes trajektoriju. Spēcīgi rādītāji parasti noved pie augstākiem vērtējumiem.

Access this data via the Eulerpool API

Bilance — Biocept

Visas kategorijas